Boryung eager to license out novel angiotensin II receptor antagonist

Published: 2009-01-19 06:59:00

Updated: 2009-01-19 06:59:00

With its new angiotensin II receptor blocker, Fimasartan, Boryung Pharm is seeking partners that can progress further clinical trial and market in US or EU in the future.

Fimasartan is a novel, non-peptide angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, curren...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK